Press release
Congestive Heart Failure Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight
Congestive Heart Failure Treatment Market
(Albany, USA) DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical, and forecasted epidemiology as well as the CHF market trends in the US, EU4 (Germany, France, Italy, Spain), and the UK, and Japan.
The Congestive Heart Failure market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Congestive Heart Failure market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Congestive Heart Failure treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Congestive Heart Failure market.
Discover Key Insights into the Chronic Heart Failure Market with DelveInsight's In-Depth Report @ Chronic Heart Failure Market Size [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Chronic Heart Failure Market Report
* In April 2025, AskBio Inc., announced a study of phase 2 study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age >18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF.
* In December 2024:- AstraZeneca- A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure. The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF). This is a Phase IIb randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetic (PK) of AZD5462 on top of standard of care in 2 cohorts of participants with HF: Cohort A, and Cohort B.
* In December 2024:- Regeneron Pharmaceuticals- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction. This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
* Driven by multiple factors, the number and distribution of reported cases of CHF have increased over time in the 7MM, among which the US contributed the major patient share.
* As per DelveInsight's estimate, the total diagnosed prevalent cases of CHF in the 7MM were approximately 20,360,000 in 2023.
* In 2023, the percentage of diagnosed prevalence of males with heart failure in the US was 55%, and that for females was 45%.
* In the UK, among all the four NYHA Classes of heart failure, Class II accounted for around 45% of the total diagnosed prevalent heart failure cases in 2023.
* Among the EU4, the highest number of diagnosed prevalent cases of CHF were found in Germany, followed by France, and Spain, and the lowest number of diagnosed prevalent cases in Italy in 2023.
* In Japan, the age-specific dignosed prevalent cases of heart failure in 2023 accounted for approximately 4,444,000 (for age group more than 60 years), 634,900 (for age group 40-59 years), and 211,600 (for age group below 39 years).
* The leading Chronic Heart Failure Companies such as Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others.
* Promising Chronic Heart Failure Therapies such as Ertugliflozin, Metolazone, AZD5462, Vericiguat (Verquvo, BAY1021189), mRNA-0184, rhNRG-1, and others.
Stay ahead in the Chronic Heart Failure Therapeutics Market with DelveInsight's Strategic Report @ Chronic Heart Failure Market Outlook [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Chronic Heart Failure Epidemiology Segmentation in the 7MM
* Total Chronic Heart Failure Diagnosed Prevalent Cases
* Chronic Heart Failure Gender-Specific Cases
* Chronic Heart Failure Ejection fraction-specific cases
* Chronic Heart Failure NYHA class-specific cases
* Chronic Heart Failure Type-specific cases
* Chronic Heart Failure Age-specific cases
Download the report to understand which factors are driving Chronic Heart Failure epidemiology trends @ Chronic Heart Failure Prevalence [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Marketed Congestive Heart Failure Drugs
* INJECTAFER (ferric carboxymaltose injection)/FERINJECT: American Regent, Vifor, and Daiichi Sankyo
INJECTAFER (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with heart failure; Iron Deficiency Anemia (IDA) in adult and pediatric patients 1-year of age and older who have either intolerance to oral iron or unsatisfactory response to oral iron; and adult patients with IDA who have non-dialysis dependent chronic kidney disease. Its dosing for iron deficiency in adult patients with heart failure and NYHA class II/III is based on patient weight and hemoglobin level starting at a single 500mg dose up to two 1000mg doses separated by six weeks.
* INPEFA (sotagliflozin): Lexicon Pharmaceuticals and Viatris
INPEFA (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as SGLT2 and SGLT1. SGLT2 is responsible for glucose reabsorption by the kidney, and SGLT1 is responsible for glucose absorption in the gastrointestinal tract. In May 2023, Lexicon Pharmaceuticals announced that the US FDA had approved INPEFA (sotagliflozin) to reduce the risk of cardiovascular death, hHF, and uHF visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. The broad label encompasses heart failure patients across the full range of LVEF, including HFpEF and HFrEF, and for patients with or without diabetes. The approval of INPEFA in heart failure indication, along with the breadth of the label, is a major milestone in Lexicon's path to fulfilling its mission of pioneering medicines that transform patients' lives.
Chronic Heart Failure Emerging Drugs
* Omecamtiv mecarbil: Cytokinetics
Omecamtiv mecarbil is a selective small-molecule cardiac myosin activator. It is designed to directly target the contractile mechanism or pumping function of the heart. By stimulating cardiac myosin, a protein responsible for converting chemical energy into the mechanical force that helps the heart contract, omecamtiv mecarbil may improve cardiac muscle performance. Preclinical research has shown that cardiac myosin activators increase cardiac contractility without affecting intracellular myocyte calcium concentrations or myocardial oxygen consumption. It has completed its Phase III for CHF and its Phase III for HFrEF is anticipated in the fourth quarter of 2024.
* KERENDIA (finerenone): Bayer
Finerenone is a nonsteroidal, selective Mineralocorticoid Receptor (MR) antagonist that has been shown to block the harmful effects of MR overactivation. MR overactivation contributes to Chronic Kidney Disease (CKD) progression and cardiovascular damage, which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Finerenone is marketed as KERENDIA or, in some countries, as FIRIALTA, and approved for the treatment of adult patients associated with Type II Diabetes (T2D) in more than 90 countries worldwide, including in China, Europe, Japan, and the US. It has completed its Phase III trial for heart and left ventricular ejection fraction =40% and the company is anticipating the first submission of the drug by mid-2025.
Get In-Depth Knowledge on Chronic Heart Failure Market Trends and Forecasts with DelveInsight @ Chronic Heart Failure Treatment Market [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Chronic Heart Failure Companies
Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others
Chronic Heart Failure Market Outlook
After a scarcity of sustainable new therapies for more than a decade, new classes of agents for the treatment of patients with CHF were approved by the US FDA - VERQUVO (vericiguat), ENTRESTO (sacubitril/valsartan), a combined Angiotensin Receptor-neprilysin Inhibitor (ARNI) and CORLANOR (ivabradine), a sinoatrial node modulator. Both drugs are recommended for use as part of a comprehensive medical therapy regimen. Recently approved INJECTAFER (ferric carboxymaltose injection)/FERINJECT by American Regent, Vifor, and Daiichi Sankyo and INPEFA (sotagliflozin) by Lexicon Pharmaceuticals and Viatris, in 2023 are the newest additions for treating heart failure. These drugs are indicated for the treatment of iron deficiency in adult patients with heart failure and to reduce the risk of cardiovascular death, hHF, and uHF visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors, respectively. VERQUVO is a stimulator of soluble guanylate cyclase.
Chronic Heart Failure Drugs Market
Currently, heart failure treatment depends on angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Other therapies, such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, and nitrates, are used to treat patients affected by heart failure. The majority of therapies are prescribed in combination, and beta-blockers are one of the most prescribed classes. Among the approved therapies, ENTRESTO is Novartis' one of the most important drugs, and its revenue is expected to rise in the next years. At present, ENTRESTO leads the CHF market among the approved therapies.
Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Heart Failure Market Report @ Chronic Heart Failure Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Chronic Heart Failure Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Chronic Heart Failure Companies- Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others.
* Chronic Heart Failure Therapies- Ertugliflozin, Metolazone, AZD5462, Vericiguat (Verquvo, BAY1021189), mRNA-0184, rhNRG-1, and others.
* Chronic Heart Failure Market Dynamics: Chronic Heart Failure Market Drivers and Barriers
* Chronic Heart Failure Unmet Needs, KOL's views, Analyst's views, Chronic Heart Failure Market Access and Reimbursement
Table of Content
1. Key Insights
2. Chronic Heart Failure Report Introduction
3. Chronic Heart Failure Executive Summary
4. Chronic Heart Failure Market Overview at a Glance
5. Chronic Heart Failure Key Events
6. Chronic Heart Failure Epidemiology and Market Forecast Methodology
7. Chronic Heart Failure Disease Background and Overview
9. Chronic Heart Failure Epidemiology and Patient Population
10. Patient Journey
11. Chronic Heart Failure Marketed Drugs
12. Chronic Heart Failure Emerging Drugs
13. Chronic Heart Failure: 7MM Analysis
14. Chronic Heart Failure Unmet needs
15. Chronic Heart Failure SWOT Analysis
16. Chronic Heart Failure KOL Views
17. Chronic Heart Failure Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=congestive-heart-failure-treatment-market-2034-ema-pdma-fda-approvals-medication-nice-approvals-clinical-trials-revenue-statistics-therapies-prevalence-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Congestive Heart Failure Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight here
News-ID: 4030925 • Views: …
More Releases from ABNewswire
Idiopathic Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.
The…
Global Sound Reinforcement Market Set to Grow at 4.28% CAGR, Reaching USD 38.58 …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
The global sound reinforcement market [https://www.arizton.com/market-reports/sound-reinforcement-market-size-growth] is projected to expand from USD 30 billion in 2024 to USD 38.58 billion by 2030, growing at a steady 4.28% CAGR, according to Arizton. This growth is being driven by rising demand for high-quality audio solutions across live events and entertainment venues. Advances in audio technology have significantly enhanced…
Gelt Raises $13M Series A to Expand AI-Powered Tax Solutions for Real Estate Inv …
Miami, FL - September 30, 2025 - Gelt [https://www.joingelt.com/], the first AI-native tax firm for investors and the Top 1% in the U.S., today announced it has raised $13 million in Series A [https://www.businesswire.com/news/home/20250930325477/en/Gelt-the-First-AI-Native-Tax-Firm-Raises-%2413M-in-Series-A-Funding-to-Transform-Tax-Strategy-Into-Year-Round-Wealth-Optimization], bringing its total funding to $21.2 million. Global investors, Zvi Limon of the Rimon Group, Vintage Investment Partners, and TLV Partners led the funding. As part of the launch, Yoram Tietz, former Managing Partner at EY…
Applications of 5-50mm security camera lens
The application scenarios of 5-50 mm surveillance lenses are primarily categorized according to the variations in field of view resulting from changes in focal length. The specific applications are as follows:
1. Wide-angle range (5-12 mm)
Panoramic monitoring for confined spaces A focal length of 5-8 mm (with a field of view of 60 degrees -90 degrees ) is suitable for enclosed small areas within 5 times 5 meters, such as elevator…
More Releases for Heart
Heart Healthy Foods and Supplements vs Heart Conditions
Heart conditions remain a major health concern worldwide, but the good news is that specific heart healthy foods and supplements can significantly improve cardiovascular health.
Scientific research has demonstrated that certain foods, nutrients and supplements support heart function, reduce inflammation, and lower the risk of heart disease.
Top Heart Healthy Foods
Fatty Fish - Salmon, mackerel, and sardines are rich in omega-3 fatty acids, which help lower blood pressure and reduce inflammation. A…
Centrifugal Heart Pumps Market | Abbott Laboratories, Abiomed, Berlin Heart, Car …
The global centrifugal heart pumps market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the centrifugal heart pumps market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr
When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue…
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH…
HEART PUMP DEVICES Market 2020 | SWOT Analysis By Top Players Abbott Laboratorie …
A detailed study on HEART PUMP DEVICES Market formulated by Brandessence Market Research, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industry's size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in…
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot
Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after…
